Mankind Pharma Ltd’s acquisition of Bharat Serums and Vaccines Ltd (BSV) for INR136.3bn ($1.6bn) was without doubt the showstopper in 2024. As private equity (PE) firm Advent profitably exited BSV, the deal left Mankind seeking INR100bn in funds for the global toehold, R&D platform and niche therapy strength offered by the acquired company.
What Will Fuel M&A Fire In 2025, Will PE Firms Star In Biggest Deals In India Again?
CRDMOs In Focus Amid China Decoupling
PE firms Advent and Carlyle drove the biggest M&A deals in human and animal pharmaceuticals in India during 2024, a year that also saw Lupin strike deals with Eli Lilly and Boehringer Ingelheim to further its ambitions in the fast-growing diabetes space. Which segments look hot and what are the expected trends for deal making in 2025?
More from Scrip Perspectives
• By
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
• By
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Scrip surveys some of the more interesting Phase III clinical trial readouts expected this year.
More from Deals
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
• By
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.